Pioneer Therapeutics

Pioneer Therapeutics is a biotechnology company focused on developing first-in-class small molecule inhibitors targeting pioneer transcription factors. These factors are unique in their ability to access closed chromatin and initiate gene expression programs that drive cancer progression and resistance. By disrupting the function of these master regulators, Pioneer Therapeutics aims to provide new treatment options for patients with refractory solid tumors, including prostate and breast cancers. The company leverages a proprietary platform to identify and optimize molecules that can selectively inhibit these previously undruggable targets.